SpermSelect Molecular sperm selection strategy to improve assisted reproductive techniques’ success

  • Edition: 2017
  • Research center: Universidad del País Vasco
  • Scientific Area: Human physiology
  • Business area: Medical Devices
  • Status: In development
  • Contact: nerea.subiran@ehu.eus

Over 180 million people worldwide have infertility issues, with male factor problems accounting for 30% to 50% of cases. Patients can make use of assisted reproductive techniques (ART), although only a third of these cases will result in live births. Establishing robust sperm quality indicators could help improve that figure.

Goals

  • To develop a low cost kit for sperm cell selection based on a molecular biomarker.

See project infographic:

Infographic

Problem to Solve

Sperm quality has traditionally been measured based on morphological and physiological parameters, which is often an inaccurate approach, especially as there are sometimes significant variations between samples from the same individual.

Sperm cell selection techniques routinely used within ARTs mostly rely on measuring motility or a forced passage through a differential gradient. More sophisticated testing is urgently required.

Innovation

The SpermSelect team has determined the presence of a protein in the sperm cell membrane that could be used for selection during ARTs. In preliminary testing, sperm sorted using this new biomarker improved the pregnancy rates achieved through intracytoplasmic sperm injection, a type of ART, by around 20%.

Level of Innovation

The fact that the biomarker is on the cell surface makes it a good candidate for sorting using an antigen-antibody technique, which is crucial to select live sperm cells ready to be used in ARTs. A low cost, quick and useful kit could therefore be developed for use in fertility centres.

Team

Project leader

Nerea Subirán

Universidad del País Vasco

Head of Innovation and Tech Transfer Officer

Gorka Artola

Universidad del País Vasco

Postdoctoral scientist

Marta Gianzo

Universidad del País Vasco

Mentor

Research Director

Clara Campàs

Kern Pharma SL

Partners

Obra social “la Caixa”
Caixa Capital Risc